Research programme: rare genetic disorder therapeutics - Recursion Pharmaceuticals

Drug Profile

Research programme: rare genetic disorder therapeutics - Recursion Pharmaceuticals

Alternative Names: Inborn genetic disorder therapeutics - Recursion Pharmaceuticals; REC-0000382; REC-0000716; REC-0001202; REC-0001571

Latest Information Update: 27 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Recursion Pharmaceuticals
  • Class Antianaemics; Neuropsychotherapeutics; Skin disorder therapies; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inborn genetic disorders

Most Recent Events

  • 09 Oct 2017 Recursion Pharmaceuticals plans a clinical trial for Inborn genetic disorders in 2018
  • 28 Jun 2017 Recursion Pharmaceuticals announces intention to submit IND application to the US FDA for Inborn genetic disorders
  • 11 Mar 2015 Preclinical trials in Inborn genetic disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top